Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab versus placebo after definitive chemoradiotherapy in unresectable stage III non-small cell lung cancer without progression
CTR20181576Phase 3Active
- Sponsor
- MedImmune
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Jan 2020; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20181576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181576.